Precision Targeting of the Gut Microbiome for Cancer Immunotherapy

P. Lombardi; David James PINATO

doi:10.1158/2159-8290.CD-24-0538

Precision Targeting of the Gut Microbiome for Cancer Immunotherapy

P. Lombardi
, David James PINATO

Dipartimento di Medicina Traslazionale

Risultato della ricerca: Contributo su rivista › Recensione in rivista › peer review

Abstract

Transforming gut microbial status from a prognostic trait to a therapeutic target is a key goal to understand and reverse resistance to anticancer immunotherapy. Glitza and colleagues propose selective manipulation of the gut microbiome with SER401 following antibiotic preconditioning and highlight multiple challenges in delivering microbiome manipulation to the clinic.

Lingua originale	Inglese
pagine (da-a)	1140-1142
Numero di pagine	3
Rivista	Cancer Discovery
Volume	14
Numero di pubblicazione	7
DOI	https://doi.org/10.1158/2159-8290.CD-24-0538
Stato di pubblicazione	Pubblicato - 2024

OSS delle Nazioni Unite

Questo processo contribuisce al raggiungimento dei seguenti obiettivi di sviluppo sostenibile

SDG 3 Salute e benessere

Accesso al documento

10.1158/2159-8290.CD-24-0538

https://hdl.handle.net/11579/202275

Altri file e collegamenti

handle

Cita questo

@article{82c80b4f35dc470d95d278ebdb65203d,

title = "Precision Targeting of the Gut Microbiome for Cancer Immunotherapy",

abstract = "Transforming gut microbial status from a prognostic trait to a therapeutic target is a key goal to understand and reverse resistance to anticancer immunotherapy. Glitza and colleagues propose selective manipulation of the gut microbiome with SER401 following antibiotic preconditioning and highlight multiple challenges in delivering microbiome manipulation to the clinic.",

author = "P. Lombardi and PINATO, \{David James\}",

year = "2024",

doi = "10.1158/2159-8290.CD-24-0538",

language = "English",

volume = "14",

pages = "1140--1142",

journal = "Cancer Discovery",

issn = "2159-8274",

publisher = "American Association for Cancer Research Inc.",

number = "7",

}

TY - JOUR

T1 - Precision Targeting of the Gut Microbiome for Cancer Immunotherapy

AU - Lombardi, P.

AU - PINATO, David James

PY - 2024

Y1 - 2024

N2 - Transforming gut microbial status from a prognostic trait to a therapeutic target is a key goal to understand and reverse resistance to anticancer immunotherapy. Glitza and colleagues propose selective manipulation of the gut microbiome with SER401 following antibiotic preconditioning and highlight multiple challenges in delivering microbiome manipulation to the clinic.

AB - Transforming gut microbial status from a prognostic trait to a therapeutic target is a key goal to understand and reverse resistance to anticancer immunotherapy. Glitza and colleagues propose selective manipulation of the gut microbiome with SER401 following antibiotic preconditioning and highlight multiple challenges in delivering microbiome manipulation to the clinic.

UR - https://iris.uniupo.it/handle/11579/202275

U2 - 10.1158/2159-8290.CD-24-0538

DO - 10.1158/2159-8290.CD-24-0538

M3 - Literature review

SN - 2159-8274

VL - 14

SP - 1140

EP - 1142

JO - Cancer Discovery

JF - Cancer Discovery

IS - 7

ER -

Precision Targeting of the Gut Microbiome for Cancer Immunotherapy

Abstract

OSS delle Nazioni Unite

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo